Skip to Content

Bexsero Approval History

FDA Approved: Yes (First approved January 23, 2015)
Brand name: Bexsero
Generic name: meningococcal group B vaccine
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Meningitis, Meningococcal

Bexsero (meningococcal group B vaccine) is a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.

Development History and FDA Approval Process for Bexsero

DateArticle
Jan 23, 2015Approval FDA Approves Bexsero Vaccine to Prevent Serogroup B Meningococcal Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide